Biosimilar Litigations include litigations relating to biosimilar/follow-on products of CDER-listed reference products. Litigations between biosimilar applicants/manufacturers and reference ...

Samsung Bioepis received approval for two biosimilars of denosumab that are interchangeable with Prolia and Xgeva. Ospomyv provided similar BMD increases as Prolia for women with osteoporosis in a ...

That suggests that we're probably missing the presence of some variable there—for example, access to care—that may be explaining those differences. So, really making sure that we are attending ...

For example, they may have lower rates of breast cancer screening or receive worse ratings of patient experience measures as a consequence of the disaster. It might be unfair to compare them to ...

As examples of some of the newer, expensive treatments coming through that would need to be funded somehow, Heafield cited CAR-T and gene therapies. NHS biosimilar uptake The NHS has a steep ...

Novartis' Sandoz division has filed its biosimilar of Humira in the US, aiming to take a share of its multi-billion dollar revenues once its patent expires. The generics and biosimilars arm of ...

Despite recent legislation capping insulin prices and manufacturer assistance programs, some people with diabetes who require insulin still encounter barriers to obtaining a reliable supply.

The FDA has approved two new biosimilars of denosumab to treat ... according to a study published in Pediatric Rheumatology.

Number 4: The FDA and European Medicines Agency (EMA) granted approval, with interchangeability in the US, to Samsung Bioepis ...

Visit us on Facebook. Opens in a new tab or window Visit us on X. Opens in a new tab or window Visit us on Instagram. Opens in a new tab or window Visit us on LinkedIn. Opens in a new tab or ...

For example, a pharmacist should never hesitate to assist a patient with obtaining a low-income subsidy. However, when a patient asks a pharmacist or pharmacy employee about which plan is best ...

Samsung Bioepis’ biosimilars Ospomyv and Xbryk have been approved to be interchangeable with Prolia/Xgeva treat osteoporosis and multiple myeloma/bone metastases from solid tumors. The FDA has ...